drugset / Trial / NCT04147338

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

NCT04147338

Phase 1 Completed 440 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the serum concentration of guselkumab after administration using three different devices in healthy participants.

Timeline

Start
2019-10-30
Primary completion
2021-09-13
Completion
2021-12-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Guselkumab Monoclonal antibody Subcutaneous

Indications

No indication recorded.